Page 20 - TD-4-3

Tumor Discovery FBXW7 in Leukemia

doi: 10.1002/cncr.35433 activities and structure-activity relationship. Eur J Med
Chem. 2024;278:116821.
44. Zhao Y, Huang Y, Jiang L, et al. Impact of different CEBPA
mutations on therapeutic outcome in acute myeloid doi: 10.1016/j.ejmech.2024.116821
leukemia. Ann Hematol. 2024;103(9):3595-3604.
56. Yang Y, Xie Q, Hu C, et al. F-box proteins and gastric
doi: 10.1007/s00277-024-05884-9 cancer: an update from functional and regulatory
mechanism to therapeutic clinical prospects. Int J Med Sci.
45. Lin ZK, Zhang R, Ge Z, et al. Characteristics of NOTCH1
mutation in adult T-cell acute lymphoblastic leukemia. 2024;21(8):1575-1588.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(6):1403-1408. doi: 10.7150/ijms.91584
doi: 10.7534/j.issn.1009-2137.2013.06.008 57. Bao E, Zhou Y, He S, et al. RING box protein-1(RBX1), a key
component of SCF E3 ligase, induced multiple myeloma cell
46. Takahashi T, Tsukuda H, Itoh H, Kimura H, Yoshimoto M, drug-resistance though suppressing p27. Cancer Biol Ther.
Tsujisaki M. Primary and isolated adult T-cell 2023;24(1):2231670.
leukemia/lymphoma of the bone marrow. Intern Med.
2011;50(20):2393-2396. doi: 10.1080/15384047.2023.2231670
doi: 10.2169/internalmedicine.50.5857 58. Fan J, Bellon M, Ju M, et al. Clinical significance of
FBXW7 loss of function in human cancers. Mol Cancer.
47. Kraszewska MD, Dawidowska M, Kosmalska M, et al. 2022;21(1):87.
BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in
T-cell acute lymphoblastic leukemia patients. Blood Cells doi: 10.1186/s12943-022-01548-2
Mol Dis. 2013;50(1):33-38. 59. Bivik Stadler C, Arefin B, Ekman H, Thor S. PIP degron-
doi: 10.1016/j.bcmd.2012.09.001 stabilized Dacapo/p21(Cip1) and mutations in ago act
in an anti- versus pro-proliferative manner, yet both
48. Wu X, Wang F, Yang X, et al. Advances in drug delivery trigger an increase in Cyclin E levels. Development.
systems for the treatment of acute myeloid leukemia. Small.
2024;20(42):e2403409. 2019;146(13):dev175927.
doi: 10.1242/dev.175927
doi: 10.1002/smll.202403409
60. Knudsen ES, Witkiewicz AK, Rubin SM. Cancer takes many
49. Di Fiore R, Suleiman S, Drago-Ferrante R, et al. The
role of FBXW7 in gynecologic malignancies. Cells. paths through G1/S. Trends Cell Biol. 2024;34(8):636-645.
2023;12(10):1415. doi: 10.1016/j.tcb.2023.10.007
doi: 10.3390/cells12101415 61. Fagundes R, Teixeira LK. Cyclin E/CDK2: DNA replication,
replication stress and genomic instability. Front Cell Dev
50. Zhu Q, Hu L, Guo Y, Xiao Z, Xu Q, Tong X. FBW7 in
hematological tumors. Oncol Lett. 2020;19(3):1657-1664. Biol. 2021;9:774845.
doi: 10.3389/fcell.2021.774845
doi: 10.3892/ol.2020.11264
62. Ruan F, Ruan Y, Gu H, Sun J, Chen Q. Clitocine enhances the
51. Takeishi S, Nakayama KI. Role of Fbxw7 in the maintenance
of normal stem cells and cancer-initiating cells. Br J Cancer. drug sensitivity of colon cancer cells by promoting FBXW7-
2014;111(6):1054-1059. mediated MCL-1 degradation via inhibiting the A2B/cAMP/
ERK axis. Am J Physiol Cell Physiol. 2024;327(4):C884-C900.
doi: 10.1038/bjc.2014.259
doi: 10.1152/ajpcell.00310.2024
52. Hu Y, Bruinstroop E, Hollenberg AN, Fliers E, Boelen A.
The role of WD40 repeat-containing proteins in endocrine 63. Song X, Shen L, Tong J, et al. Mcl-1 inhibition overcomes
intrinsic and acquired regorafenib resistance in colorectal
(dys) function. J Mol Endocrinol. 2023;71(1):e220217.
cancer. Theranostics. 2020;10(18):8098-8110.
doi: 10.1530/JME-22-0217
doi: 10.7150/thno.45363
53. Liang J, Yu M, Li Y, Zhao L, Wei Q. Glycogen synthase 64. Fowler-Shorten DJ, Hellmich C, Markham M,
kinase-3: A potential immunotherapeutic target in tumor Bowles KM, Rushworth SA. BCL-2 inhibition in
microenvironment. Biomed Pharmacother. 2024;173:116377.
haematological malignancies: Clinical application and
doi: 10.1016/j.biopha.2024.116377 complications. Blood Rev. 2024;65:101195.
54. Cheng Y, Li G. Role of the ubiquitin ligase Fbw7 in cancer doi: 10.1016/j.blre.2024.101195
progression. Cancer Metastasis Rev. 2012;31(1-2):75-87.
65. Vazquez-Ulloa E, Lin KL, Lizano M, Sahlgren C. Reversible
doi: 10.1007/s10555-011-9330-z and bidirectional signaling of notch ligands. Crit Rev
Biochem Mol Biol. 2022;57(4):377-398.
55. Zeng J, Chen Z, He Y, et al. A patent review of SCF E3 ligases
inhibitors for cancer: Structural design, pharmacological doi: 10.1080/10409238.2022.2113029

Volume 4 Issue 3 (2025) 12 doi: 10.36922/TD025150027